

REMARKS

This amendment is being filed prior to payment of the issue fee to correct typographical errors and does not change the scope of the claims. After amending the claims as set forth above, claims 4, 6, 7, 15-17, 23-27, and 30-33 are now pending in this application.

Claim 7 is currently being amended to correct a typographical error by replacing " R' " with --R¹--. Claims 4, 6, and 7 are currently being amended to correct a typographical error in the definition for carboxyl by replacing " therof " with --thereof--. Entry of the amendment is requested.

An Examiner's Amendment was previously made on January 17, 2008. Pursuant to the telephonic interview with Hugo M. Eng on February 11, 2008, it was suggested that the amendments of January 17, 2008 be incorporated into the claims so that the status identifiers and markings reflect only the amendments currently made by the Applicant. Accordingly, the corrections have been made and the following Examiner's amendments have thus been incorporated into the claims without markings:

- Addition of --(Formula IB)-- beneath the structure in claim 4;
- Deletion of the terms "a lipid, an amino acid, a carbohydrate, a peptide" from the W, W², and W³ definition in claim 4;
- Deletion of the provisos indicated by a), c), and d) at the end of claim 4;
- Deletion of the prefix b) at the end of claim 4;
- Replacement of the term "thereofm" with --thereof-- in the definition of phosphonate (phosponate refers to ...and salts thereof) in claim 4;
- Addition of --(Formula IC)-- beneath the structure in claim 6;
- Deletion of the terms "a lipid, an amino acid, a carbohydrate, a peptide" from the W, W², and W³ definition in claim 6;
- Addition of --(Formula IC-A)-- beneath the structure in claim 7;
- Deletion of the terms "a lipid, an amino acid, a carbohydrate, a peptide" from the W, W², and W³ definition in claim 7;

- Replacement of the term “thereofm” with --thereof-- in the definition of phosphonate (phosponate refers to ...and salts thereof) in claim 7;
- Deletion of the term “(-S or R-)” from the fourth compound in claim 30;
- Replacement of the term “β-ribofuranosyl” with --β-D-ribofuranosyl-- in the 14th compound in claim 30.
- Deletion of the term “or mixture of compounds” in claim 31.
- Deletion of the term “or mixtures of one or more compounds” in claim 32.

The Examiner is invited to contact the undersigned if a telephone interview would expedite issuance of the current application.

Respectfully submitted,

Date 11 April 2008

By 

FOLEY & LARDNER LLP
Customer Number: 77977
Telephone: (650) 251-1126
Facsimile: (650) 856-3710

Hugo M. Eng, Ph.D.
Registration No. 50,840